Niagen Bioscience CEO Robert Fried discusses the science of NAD, the problems with the supplement industry, and how his company is leading the way in anti-aging research.

Executives from Niagen Bioscience, Pushly, and VidaCorp discuss brand evolution. Learn why authenticity, community, and AI are key to building a resilient brand.

Niagen Bioscience can either commercialise the drug candidate independently or sublicense to a strategic pharmaceutical ...

Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine ...

View the latest Niagen Bioscience Inc. (NAGE) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Niagen Bioscience Inc. (NASDAQ:NAGE) saw its stock rise 2% after securing an exclusive global commercial license from Norway’s Haukeland University Hospital to develop its nicotinamide riboside ...

This initiative is part of the brand’s commitment to providing guests with science-backed health and wellness services.

Niagen Bioscience Media Contact: Kendall Knysch, Senior Director of Media Relations & Partnerships 310-405-5227 [email protected]. Niagen Bioscience Investor Relations Contact: ...

Niagen Bioscience (NASDAQ:NAGE) is preparing to release its quarterly earnings on Wednesday, 2025-05-07. Here's a brief overview of what investors should keep in mind before the announcement.

LOS ANGELES, June 11, 2025--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of ...